Published in Ann Rheum Dis on June 01, 1985
Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis (1995) 2.10
Bone mass in patients with rheumatoid arthritis. Ann Rheum Dis (1992) 1.77
Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis (1995) 1.73
Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity. Ann Rheum Dis (1993) 1.61
Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res (1999) 1.59
Alterations in appendicular skeletal mass in patients with rheumatoid, psoriatic, and osteoarthropathy. Ann Rheum Dis (1988) 1.38
Measurement of hand bone mineral content by dual energy x-ray absorptiometry: development of the method, and its application in normal volunteers and in patients with rheumatoid arthritis. Ann Rheum Dis (1994) 1.11
Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis--a population based study. Ann Rheum Dis (1994) 1.01
Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. Ann Rheum Dis (2007) 1.01
Bone quality and bone mass as assessed by quantitative ultrasound and dual energy x ray absorptiometry in women with rheumatoid arthritis: relationship with quadriceps strength. Ann Rheum Dis (2002) 0.90
The utility of clinical decision tools for diagnosing osteoporosis in postmenopausal women with rheumatoid arthritis. BMC Musculoskelet Disord (2008) 0.84
Bone mineral density in nonsteroid treated early rheumatoid arthritis. Ann Rheum Dis (1994) 0.84
Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis. Rheumatol Int (2011) 0.81
Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage. Rheumatol Int (2012) 0.79
Physical activity as a determinant of bone conservation in the radial diaphysis in rheumatoid arthritis. Ann Rheum Dis (1993) 0.78
Clinical assessment of disease activity in rheumatoid arthritis: evaluation of a functional test. Ann Rheum Dis (1988) 0.78
Skeletal complications of rheumatoid arthritis. Osteoporos Int (2017) 0.75
The effect of low-dose prednisone on bone mineral density in Peruvian rheumatoid arthritis patients. Rheumatol Int (2003) 0.75
Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet (1984) 2.85
Total body calcium in rheumatoid arthritis: effects of disease activity and corticosteroid treatment. Br Med J (Clin Res Ed) (1982) 2.24
Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem (1981) 1.99
Osteoporosis of rheumatoid arthritis: influence of age, sex and corticosteroids. Arthritis Rheum (1967) 1.98
Serum biochemical values in rheumatoid disease. Ann Rheum Dis (1971) 1.77
Liver disease in rheumatoid arthritis and Sjøgren's syndrome. Prospective study using biochemical and serological markers of hepatic dysfunction. Ann Rheum Dis (1975) 1.66
Bone mineral content in the forearm measured by photon absorptiometry. Principles and reliability. Scand J Clin Lab Invest (1975) 1.65
Immobilization and bone. Calcif Tissue Int (1983) 1.59
Bone mineral density in rheumatoid arthritis measured by the gamma transmission method. Scand J Rheumatol (1975) 1.42
Osteoporosis in rheumatoid arthritis. A follow-up study. Acta Rheumatol Scand (1968) 1.39
Prevalence of decreased bone mass in rheumatoid arthritis. Relation to anti-inflammatory treatment. Clin Rheumatol (1984) 1.27
Long-term reproducibility of bone mineral content measurements. Scand J Clin Lab Invest (1977) 1.19
Diagnostic procedures in disorders of calcium metabolism. Clin Endocrinol (Oxf) (1978) 1.14
Relationship between local and total bone mineral in patients with rheumatoid arthritis and normal subjects. Clin Rheumatol (1983) 1.07
Bone loss in patients with rheumatoid arthritis. Scand J Rheumatol (1975) 1.05
Bone remodeling and calcium metabolism: a correlated histomorphometric, calcium kinetic, and biochemical study in patients with osteoporosis and Paget's Disease. Metabolism (1977) 0.93
An easy and reliable method for determination of urinary hydroxyproline. Clin Chim Acta (1984) 0.92
Proceedings: Bone mineral determinations on long-term diabetics. AJR Am J Roentgenol (1976) 0.87
Bone mineral content before and after intestinal bypass operation in obese patients. Acta Med Scand (1981) 0.85
An easy procedure for in vivo estimation of protein binding and correction of elevated serum values induced by venous stasis. Clin Chim Acta (1975) 0.84
[Treatment of diabetes with insulin]. Zhonghua Yi Xue Za Zhi (1984) 0.81
The diagnosis of osteoporosis. J Bone Miner Res (1994) 10.90
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med (1997) 6.15
Bacterial genome sizes determined by DNA renaturation studies. J Gen Microbiol (1970) 5.86
Serological cross-reactions between Mycoplasma genitalium and Mycoplasma pneumoniae. J Clin Microbiol (1984) 3.15
Genome size of mycoplasmal DNA. Nature (1969) 2.86
Prediction of rapid bone loss in postmenopausal women. Lancet (1987) 2.76
Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. Br Med J (1973) 2.60
Bone-density measurement. Lancet (1992) 2.38
Letter: Anticonvulsant hypomagnesaemia. Br Med J (1974) 2.30
Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ (1991) 2.12
Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest (1980) 2.04
Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. N Engl J Med (1987) 2.03
Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int (2002) 2.01
Complete DNA sequence of yeast chromosome II. EMBO J (1994) 1.97
Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res (1999) 1.95
Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem (1994) 1.93
The sequence of 16S rRNA from Mycoplasma strain PG50. DNA (1985) 1.91
Circular, repetitive DNA in yeast. Biochim Biophys Acta (1972) 1.88
A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum (2004) 1.87
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med (1998) 1.81
Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. N Engl J Med (1985) 1.81
Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet (1981) 1.81
Catalysis of DNA reassociation by the Escherichia coli DNA binding protein: A polyamine-dependent reaction. J Mol Biol (1977) 1.73
Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA (2001) 1.72
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Bone mineral content in the forearm measured by photon absorptiometry. Principles and reliability. Scand J Clin Lab Invest (1975) 1.65
Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int (2003) 1.63
Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab (1996) 1.61
Epidemiology of postmenopausal spinal and long bone fractures. A unifying approach to postmenopausal osteoporosis. Clin Orthop Relat Res (1982) 1.59
Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem (1998) 1.51
The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric (2006) 1.50
Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage (2008) 1.50
Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J Intern Med (2006) 1.49
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int (2004) 1.48
Accuracy of measurements of body composition by dual-energy x-ray absorptiometry in vivo. Am J Clin Nutr (1993) 1.48
Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone (1996) 1.45
Postmenopausal osteoporosis: therapeutic options. Climacteric (2005) 1.45
Bone Gla protein (osteocalcin) assay standardization report. J Bone Miner Res (1990) 1.45
Effect of an energy-restrictive diet, with or without exercise, on lean tissue mass, resting metabolic rate, cardiovascular risk factors, and bone in overweight postmenopausal women. Am J Med (1993) 1.44
Potential risk factors for development of postmenopausal osteoporosis--examined over a 12-year period. Osteoporos Int (1991) 1.42
Circular DNA molecules controlling synthesis and transfer of the surface antigen (K88) in Escherichia coli. J Gen Microbiol (1972) 1.41
Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes. Diabetes (1978) 1.41
Validation of body composition by dual energy X-ray absorptiometry (DEXA). Clin Physiol (1991) 1.41
Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis (2003) 1.40
Incorporation and distribution of strontium in bone. Bone (2001) 1.40
Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand (1981) 1.40
Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism (1991) 1.40
Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis (2013) 1.40
Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res (1991) 1.37
Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers (2009) 1.37
Bone mass and its relationship to age and the menopause. J Clin Endocrinol Metab (1987) 1.36
Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ (1989) 1.34
Links between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis per se? Osteoporos Int (2006) 1.33
Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int (2006) 1.33
The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab (1988) 1.33
Mechanism of circadian variation in bone resorption. Bone (2002) 1.33
Effect of puberty on rates of bone growth and mineralisation: with observations in male delayed puberty. Arch Dis Child (1979) 1.31
Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab (1991) 1.30
Efficient identification of postdischarge surgical site infections: use of automated pharmacy dispensing information, administrative data, and medical record information. J Infect Dis (1999) 1.29
Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf) (1989) 1.29
Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet (1978) 1.29
Bone mineral loss in insulin-treated diabetes mellitus: studies on pathogenesis. Acta Endocrinol (Copenh) (1979) 1.28
Treatment with vitamin D or its analogues does not change body weight or blood glucose level in postmenopausal women. Int J Obes (1984) 1.28
Age- and menopause-associated variations in body composition and fat distribution in healthy women as measured by dual-energy X-ray absorptiometry. Metabolism (1995) 1.28
Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ (1992) 1.27
Prevalence of decreased bone mass in rheumatoid arthritis. Relation to anti-inflammatory treatment. Clin Rheumatol (1984) 1.27
Calcium supplementation and postmenopausal bone loss. Br Med J (Clin Res Ed) (1984) 1.27
Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care (1995) 1.26
The transplanted parathyroid gland: evaluation of cryopreservation and other environmental factors which affect its function. Surgery (1974) 1.25
Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone (2000) 1.24
Treatment of post menopausal osteoporosis. A controlled therapeutic trial comparing oestrogen/gestagen, 1,25-dihydroxy-vitamin D3 and calcium. Clin Endocrinol (Oxf) (1982) 1.24
Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy (2009) 1.24
Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. J Clin Endocrinol Metab (1995) 1.23
Influence of menopause on serum lipids and lipoproteins. Maturitas (1990) 1.23
Bone changes occurring spontaneously and caused by estrogen in early postmenopausal women: a local or generalised phenomenon? Br Med J (Clin Res Ed) (1986) 1.22
Usefulness of regional bone measurements in patients with osteoporotic fractures of the spine and distal forearm. J Nucl Med (1987) 1.21
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int (2001) 1.20
Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment. Am J Med (1990) 1.20
The effect of glucocorticoids on bone mass in rheumatoid arthritis patients. Influence of menopausal state. Arthritis Rheum (1985) 1.19